首页> 美国卫生研究院文献>Clinical Ophthalmology (Auckland N.Z.) >Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions
【2h】

Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions

机译:Nampt / PBEF / visfatin血清水平:视网膜血管阻塞的新生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy deficits. A case–control study of 18 subjects with a history of RVO as well as six healthy volunteers is presented. Serum Nampt levels were quantified using a commercially available enzyme-linked immunosorbent assay kit. Serum Nampt levels were 79% lower in patients with a history of RVO compared with that in healthy volunteers (P<0.05). There was no statistically significant difference among the types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemiretinal vein occlusions (n=3), and central retinal artery occlusions (n=3; P=0.69). Further studies are needed to establish the temporal kinetics of Nampt expression and to determine whether Nampt may represent a novel biomarker to identify at-risk populations, or whether it is a druggable target with the potential to ameliorate the long-term complications associated with the condition, ie, macular edema, macular ischemia, neovascularization, and permanent loss of vision.
机译:这项研究的主要目的是对患有视网膜血管阻塞(RVOs),以明显的局部缺血为特征的疾病状况,和代谢能量不足。进行了一项病例对照研究,研究对象为18例具有RVO病史的受试者以及6名健康志愿者。使用可商购的酶联免疫吸附测定试剂盒对血清Nampt水平进行定量。具有RVO病史的患者的血清Nampt水平比健康志愿者低79%(P <0.05)。 RVO的类型之间无统计学差异,特别是视网膜分支静脉阻塞(n = 7),视网膜中央静脉阻塞(n = 5),半视网膜静脉阻塞(n = 3)和视网膜中央动脉阻塞(n = 3; P = 0.69)。需要进一步的研究来确定Nampt表达的时间动力学,并确定Nampt是否可以代表一种新的生物标记物来识别高危人群,或者它是否是可以缓解与该病相关的长期并发症的潜在药物目标即黄斑水肿,黄斑缺血,新血管形成和永久性视力丧失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号